Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00028021
DRKS00028021
Recruiting
Not Applicable

Characterisation of tumour heterogeneity and identification of adaptive resistance mechanisms of metastatic castration-resistant prostate carcinoma

Klinik für Nuklearmedizin am Universitätsklinikum Augsburg0 sites45 target enrollmentMarch 7, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsC61Malignant neoplasm of prostate

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
C61
Sponsor
Klinik für Nuklearmedizin am Universitätsklinikum Augsburg
Enrollment
45
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 7, 2022
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
Male

Investigators

Sponsor
Klinik für Nuklearmedizin am Universitätsklinikum Augsburg

Eligibility Criteria

Inclusion Criteria

  • •Patients between 18 and 99 years of age
  • •\- Fulfilment of the standard criteria for a 177Lu\-PSMA RLT
  • •\- Low\-risk accessibility of a PSMA\-positive lesion by percutaneous biopsy

Exclusion Criteria

  • •\- Persons who are placed in an institution by court order or by order of the authorities.
  • •\- Persons who are in a dependent relationship or employment relationship with the sponsor or investigator.
  • •\- Severe psychiatric illnesses
  • •\- Patients with congenital bleeding disorders (e.g. von Willebrand disease).

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown
Not Applicable
Comparing tumour heterogeneity in primary tumour, circulating tumour cells and metastasesSCLC niet kleincellig longcarcinoom, longkankerlungcancer, tumour heterogeneity, tumor heterogeniteit, CTC, circulating tumour cell, circulerende tumor cel
NL-OMON29203niversity Medical Centre Groningen30
Not yet recruiting
Not Applicable
Comparing tumour heterogeneity in primary tumour, circulating tumour cells and its metastaseslungcancer1002765510029107
NL-OMON45251niversitair Medisch Centrum Groningen50
Not yet recruiting
Phase 1/2
Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response.
2024-512152-38-00Fundacion Instituto De Investigacion Sanitaria De Santiago De Compostela100
Not yet recruiting
Not Applicable
Fluorodeoxyglucose (FDG) and human epidermal growth factor receptor 2 (HER2) positron emission tomography (PET) scan in breast cancerBreast cancerCancer - Breast
ACTRN12624000918527Fiona Stanley Hospital10
Completed
Not Applicable
An integrated multi-omics study of tumor heterogeneity in patients with treatment-resistant malignant cancermalignant cancer
JPRN-UMIN000040181Kansai Electric Power Hospital100